News

Ahmad Masri, MD, MS, offers perspective om the study design of the ACACIA-HCM trial and the unmet need within nonobstructive hypertrophic cardiomyopathy.

This new recommendation by the European Academy of Allergy and Clinical Immunology was put forward to help guide clinical practices.

The Patient Self-Report Survey for the Assessment of Fibromyalgia illustrated its accuracy in determining pain sensitivity and psychological factors in patients with shoulder or low back pain.

In a recent case series, a substantial percentage of patients with GA experienced "floaters" from presumed intravitreal silicone oil droplets after pegcetacoplan injection.

Ankeet Bhatt, MD, MBA provides additional perspective on a recent study examining the cost-effectiveness and health impact of sacubitril/valsartan use at different thresholds of ejection fraction.

Use of antiviral therapy was linked to a decreased risk of multiple cardiovascular outcomes and mortality compared to patients not using antiviral therapy.

Social vulnerability index, race, and poverty were associated with increased rates of CDI, calling attention to population-level health disparities.

Patients with psoriatic disease have a significantly higher risk of developing a variety of autoimmune diseases, as indicated by the Charlson Comorbidity Index.

Ankeet Bhatt, MD, MBA, offers perspective into the results of a recent analysis of the GWTG-HF registry at HFSA 2023.

This new data represents the first real-world, US-based data on this drug, demonstrating the efficacy and the safety indications of these clinical trials.

Data from a phase 1b trial presented at HFSA 2023 detail the effects of JK07, an investigational agent from Salubris Biotherapeutics, in patients with heart failure with reduced ejection fraction.

Self-injection of bimekizumab was generally well tolerated among patients with psoriatic arthritis.

On the floor at HFSA 2023, Muthiah Vaduganathan, MD, MPH, provides his perspective on the latest IV iron supplementation guidelines from the European Society of Cardiology.

This new data from 27 European countries resulted in several notable findings with regard to the journey of patients with skin disease in various healthcare environments.

A study presented at HFSA 2023 offers clinicians an overview of the influence of socioeconomic status on access to implantable hemodynamic monitors using the National Inpatient Sample.

Mazen Noureddin, MD, MHSc discusses results from the phase 2a trial of HU6 and explains its significant impact on liver fat and body weight.

Syed Ali Husain, MD, MPH, discusses the importance of kidney transplantation, waitlisting, and how disparities in access to transplantation should be addressed.

Announced on October 9, the decision to issue a CRL is based on the FDA's belief the clinical meaningfulness of patisiran’s treatment effects for the cardiomyopathy of ATTR amyloidosis had not been established.

Prespecified analysis of STEP-HFpEF trial shows semaglutide benefits consistent across ejection fraction spectrum, offering potential HFpEF management.

Hosts are joined by Marat Fudim, MD, MHS, of Duke, to discuss the REBALANCE-HF trial, which examined endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction.

DELTA-HF trial: Device-based thoracic duct decompression with the eLym system could prove beneficial in acute decompensated heart failure patients.

Slight differences in disease presentation, as well as navigating the safety discussion with parents, presents unique recommendations for pediatricians initiating invasive imaging.

The REBALANCE-HF trial at HFSA 2023 reveals that right greater splanchnic nerve ablation was well-tolerated and safe in patients with HFpEF, with additional analysis shedding light on the proportion of responders to the procedure.

Data show how care providers shifted their mindsets to prioritize efficacy, safety, tolerability and availability factors during the 2022 formula supply shortage and recall crises.

The optimization of diet and nutrition support during pediatric patients’ rehabilitation is a strategy in lieu of a comprehensively ideal guideline and requires an appreciation for the individual.

Maralixibat and odevixibat have been "game changers" for their benefit in pruritus, and clinicians are interested to learn more about their long-term hepatic benefit.

New data show a promising machine learning tool could help specialists detect fistula risks and provide more tailored, timely care in children.

A number of systemic, industry-based and cultural factors are driving an underrepresentation of minorities in clinicals.

Specialists are hindered by limited therapies and a lack of noninvasive testing methods. Martinez shares a wishlist for her colleagues.

Anand Shah, MD, MBA, provides insights into a study he led examining the impact of out-of-pocket costs and insurance type on uptake of GDMT in patients with heart failure with reduced ejection fraction.